$0.87
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Overview
52-week range
$0.45
$3.87
12% of range
Avg surprise (last 3)
+12.9%
Avg reaction (last 2)
-12.0%
0% positive
Latest IV / EM
2441%
EM ±381.4% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.04 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.04 | $-0.06 | +33.3% | +81.8% | -2.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.18 | $-0.19 | +5.3% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.22 | $-0.22 | 0.0% | — | -21.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.29 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.36 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.37 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.33 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | — | $0 | $0 | $172,000 | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | $-8M | — | $-7M | $-11M | $-12M | — | $-12M |
| Net income | $-7M | $-8M | — | $-5M | $-7M | $-13M | — | $-7M |
| EPS (diluted) | $-0.04 | $-0.04 | — | $-0.12 | $-0.18 | $-0.22 | — | $-0.24 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5M | $10M | $19M | $4M | $10M | $10M | $4M | $4M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $57M | $47M | $53M | $5M | $11M | $18M | $30M | $32M |
| Total assets | $61M | $52M | $59M | $10M | $17M | $24M | $37M | $44M |
| Long-term debt | — | — | — | $0 | $2M | $6M | $10M | $14M |
| Total liabilities | $13M | $16M | $17M | $22M | $26M | $29M | $33M | $38M |
| Total equity | $39M | $36M | $33M | $-8M | $-9M | $-5M | $2M | $6M |